US 12,281,170 B2
Senescent cell-associated antigen-binding domains, antibodies and chimeric antigen receptors comprising the same, and uses thereof
Müge Ogrunc, Paris (FR); and Thierry Mathieu, Brussels (BE)
Assigned to StarkAge Therapeutics, Lille (FR)
Filed by StarkAge Therapeutics, Lille (FR)
Filed on Jun. 23, 2023, as Appl. No. 18/340,242.
Application 18/340,242 is a division of application No. 17/032,510, filed on Sep. 25, 2020, granted, now 11,723,926.
Application 17/032,510 is a continuation in part of application No. 16/585,256, filed on Sep. 27, 2019, abandoned.
Claims priority of application No. 19200182 (EP), filed on Sep. 27, 2019.
Prior Publication US 2024/0009242 A1, Jan. 11, 2024
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); C12N 5/0783 (2010.01)
CPC C07K 16/2896 (2013.01) [A61K 39/4611 (2023.05); A61K 39/4631 (2023.05); A61K 39/464402 (2023.05); C12N 5/0636 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01)] 12 Claims
 
1. A method of treating or alleviating a senescence-related disease or disorder in a subject in need thereof, wherein said senescence-related disease or disorder is a cancer comprising DPP4-expressing cells or a fibrotic disease comprising DPP4-expressing cells, the method comprising administering to the subject a composition comprising:
an isolated antibody or antigen-binding fragment thereof comprising a DPP4-binding domain; and/or
an immune cell engineered to express at its surface a chimeric antigen receptor (CAR) comprising:
at least one extracellular binding domain, comprising said DPP4-binding domain,
an extracellular spacer domain,
a transmembrane domain,
optionally, at least one costimulatory domain, and
at least one intracellular signaling domain; and/or
a population of immune cells comprising a plurality of said engineered immune cells,
wherein said DPP4-binding domain comprises a combination of three heavy chain variable region (HCVR)'s complementary-determining regions (CDRs) and three light chain variable region (LCVR)'s CDRs, said combination being as defined in any row of the table below, wherein the CDRs are defined by their SEQ ID NO:
 
 
 VH- VH- VH- VL- VL- VL-
Clone’s name CDR1 CDR2 CDR3 CDR1 CDR2 CDR3
 
5826-13-R3A-A10 107 119 137 146 157 170
5826-13-R3A-B1 108 120 138 147 158 171
5826-13-R3A-B3 108 121 138 147 159 171
5826-13-R3A-D5 109 122 139 148 160 172
5826-13-R3A-D6 108 123 138 149 159 171
5826-13-R4A-E2 108 124 138 147 159 171
5826-13-R4A-E6 110 125 140 146 161 170
5826-13-R4A-E9 108 126 141 149 159 171
5826-13-R4A-F10 108 126 138 150 159 171
5826-13-R4A-G11 108 126 138 150 159 171
5826-13-R4A-G12 111 127 138 151 159 171
5826-13-R4A-H1 110 128 140 146 162 170
5826-13-R4A-H2 108 126 141 149 159 171
5826-13-R4A-H3 108 126 138 149 159 173
5826-13-R4A-H4 112 125 140 146 162 170
5826-13-R4A-H5 108 127 138 147 159 171
5826-13-R4A-H6 108 127 142 147 159 171
5826-13-R4A-H9 108 123 138 149 159 171
5826-13-R4A-H10 110 125 140 146 162 170
5826-13-R4A-H11 110 128 140 146 162 170
5826-13-R4A-H12 110 125 140 146 163 170